Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ChiCTR2600132189) titled 'A Study on the Efficacy, Safety, and Health Economics of Donanemab Treatment for Alzheimer's Disease in the Real World' on Sept. 10.
Study Type: Observational study
Study Design:
Sequential
Primary Sponsor: The Second Affiliated Hospital of Guangzhou Medical University
Condition:
Alzheimer 's disease
Recruitment Status: Not Recruiting
Phase: 4
Date of First Enrollment: 2026-09-17
Target Sample Size: Donanemab treatment group:200;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=342784
Published by HT Digital Content Services with permission from Hea...